Echocardiographyc and histomorphometric assessment of the effects of pharmacological antagonism of endothelin receptors in the Sugen 5416/hypoxia rat model of pulmonary hypertension

S. Cantoni (Parma, Italy), S. Cavalli (Parma, Italy), F. Pastore (Parma, Italy), R. Nassini (Florence, Italy), F. De Logu (Florence, Italy), G. Villetti (Parma, Italy), F. Facchinetti (Parma, Italy)

Source: International Congress 2018 – Experimental research in pulmonary hypertension
Session: Experimental research in pulmonary hypertension
Session type: Thematic Poster
Number: 3073
Disease area: Pulmonary vascular diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
S. Cantoni (Parma, Italy), S. Cavalli (Parma, Italy), F. Pastore (Parma, Italy), R. Nassini (Florence, Italy), F. De Logu (Florence, Italy), G. Villetti (Parma, Italy), F. Facchinetti (Parma, Italy). Echocardiographyc and histomorphometric assessment of the effects of pharmacological antagonism of endothelin receptors in the Sugen 5416/hypoxia rat model of pulmonary hypertension. 3073

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Optimization of tissue targeting properties of macitentan, a new dual endothelin receptor antagonist, improves its efficacy in a rat model of pulmonary fibrosis associated with pulmonary arterial hypertension
Source: Annual Congress 2011 - Treatment of human pulmonary hypertension
Year: 2011


Effects of AT1 receptor blockade on pulmonary and systemic manifestations in a COPD/emphysema mouse model
Source: Annual Congress 2009 - Preclinical models in drug development
Year: 2009

Dual endothelin receptor antagonism: setting standards in PAH
Source: Eur Respir Rev 2008; 17: 13-18
Year: 2007



Monitoring of liver function in patients with pulmonary hypertension treated with endothelin receptor antagonists: The value of a novel monitoring system
Source: Annual Congress 2011 - Treatment of pulmonary hypertension
Year: 2011

Endothelin receptor antagonists in pulmonary arterial hypertension
Source: Eur Respir J 2008; 31: 407-415
Year: 2008



α1-adrenoceptor antagonism does not modify the pulmonary vasoconstrictor effect of dexfenfluramine in the rat
Source: Eur Respir J 2001; 18: Suppl. 33, 491s
Year: 2001

Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment
Source: Eur Respir J 2011; 38: 851-860
Year: 2011



NTP42, an antagonist of the thromboxane receptor, attenuates experimentally-induced pulmonary arterial hypertension
Source: International Congress 2019 – Pulmonary hypertension: novelties from the bench
Year: 2019

Endothelin: setting the scene in PAH
Source: Eur Respir Rev 2008; 17: 3-7
Year: 2007



Endothelin-a receptor antagonists reduce eNOS gene expression in rats with chronic hypoxic pulmonary hypertension
Source: Eur Respir J 2003; 22: Suppl. 45, 271s
Year: 2003

Activation of the Beta-3 adrenoceptor in experimental pulmonary hypertension
Source: International Congress 2018 – Experimental research in pulmonary hypertension
Year: 2018

Dual endothelin-1 receptor antagonism prevents chronic intermittent hypoxia-induced cardiovascular alterations in rats
Source: Annual Congress 2008 - Innovative treatments in sleep disordered breathing
Year: 2008

Endothelin-1 receptor antagonists prevent the development of pulmonary emphysema in rats
Source: Eur Respir J 2010; 35: 904-912
Year: 2010



Single centre experience with endothelin receptor blockade in pulmonary hypertension
Source: Annual Congress 2004 - Pulmonary hypertension
Year: 2004


Severe pulmonary hypertension in chronic lung disease. Long term effects on gas exchange of endothelin receptor antagonists or PDE5 inhibitors
Source: Annual Congress 2011 - Pulmonary hypertension in hypoxic lung disease
Year: 2011

Is there a role for endothelin-1 receptor antagonists in the treatment of lung fibrosis associated with pulmonary hypertension?
Source: Eur Respir J, 52 (2) 1801287; 10.1183/13993003.01287-2018
Year: 2018



Goal-oriented treatment and combination therapy for pulmonary arterial hypertension
Source: Eur Respir J 2005; 26: 858-863
Year: 2005



Inhalation of endothelin receptor blockers in pulmonary hypertension
Source: Annual Congress 2008 - Pulmonary hypertension I
Year: 2008

Bosentan does not improve pulmonary hypertension and lung remodeling in heart failure
Source: Eur Respir J 2011; 37: 578-586
Year: 2011



Selective versus non-selective endothelin receptor antagonists
Source: Annual Congress 2005 - New treatments in pulmonary hypertension
Year: 2005